CN110791451A - 一株植物乳杆菌jylp-326及其对睡眠的改善应用和产品 - Google Patents
一株植物乳杆菌jylp-326及其对睡眠的改善应用和产品 Download PDFInfo
- Publication number
- CN110791451A CN110791451A CN201911164848.7A CN201911164848A CN110791451A CN 110791451 A CN110791451 A CN 110791451A CN 201911164848 A CN201911164848 A CN 201911164848A CN 110791451 A CN110791451 A CN 110791451A
- Authority
- CN
- China
- Prior art keywords
- jylp
- lactobacillus plantarum
- sleep
- product
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 35
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 35
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 35
- 230000007958 sleep Effects 0.000 title claims abstract description 16
- 239000000843 powder Substances 0.000 claims abstract description 27
- 241000894006 Bacteria Species 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 239000001888 Peptone Substances 0.000 claims description 5
- 108010080698 Peptones Proteins 0.000 claims description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 5
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 235000015278 beef Nutrition 0.000 claims description 5
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 5
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 238000011081 inoculation Methods 0.000 claims description 5
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 5
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 claims description 5
- 235000019319 peptone Nutrition 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 claims description 5
- 239000001393 triammonium citrate Substances 0.000 claims description 5
- 235000011046 triammonium citrate Nutrition 0.000 claims description 5
- 235000007164 Oryza sativa Nutrition 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 229910052564 epsomite Inorganic materials 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 235000009566 rice Nutrition 0.000 claims description 4
- 239000006872 mrs medium Substances 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 230000000813 microbial effect Effects 0.000 claims description 2
- 238000009629 microbiological culture Methods 0.000 claims description 2
- 238000011160 research Methods 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract description 11
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract description 11
- 230000006872 improvement Effects 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 abstract description 5
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 208000019901 Anxiety disease Diseases 0.000 abstract description 2
- 206010002869 Anxiety symptoms Diseases 0.000 abstract description 2
- 208000019914 Mental Fatigue Diseases 0.000 abstract description 2
- 230000036506 anxiety Effects 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 239000005556 hormone Substances 0.000 abstract description 2
- 229940088597 hormone Drugs 0.000 abstract description 2
- 208000028774 intestinal disease Diseases 0.000 abstract description 2
- 230000006996 mental state Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 230000008451 emotion Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 32
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 27
- 206010022437 insomnia Diseases 0.000 description 27
- 238000012360 testing method Methods 0.000 description 20
- 239000000047 product Substances 0.000 description 14
- 230000004622 sleep time Effects 0.000 description 11
- 230000037396 body weight Effects 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000003860 sleep quality Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000004620 sleep latency Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 230000028527 righting reflex Effects 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001052560 Thallis Species 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002267 hypothalamic effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000019468 Iatrogenic Disease Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 239000003421 short acting drug Substances 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
人数 | 空白组 | 对照组 | 试验组 |
高(0-3分) | 1 | 2 | 12 |
中(4-8分) | 10 | 16 | 36 |
低(9-16分) | 37 | 34 | 10 |
差(17分以上) | 12 | 8 | 2 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911164848.7A CN110791451B (zh) | 2019-11-25 | 2019-11-25 | 一株植物乳杆菌jylp-326及其对睡眠的改善应用和产品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911164848.7A CN110791451B (zh) | 2019-11-25 | 2019-11-25 | 一株植物乳杆菌jylp-326及其对睡眠的改善应用和产品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110791451A true CN110791451A (zh) | 2020-02-14 |
CN110791451B CN110791451B (zh) | 2020-10-02 |
Family
ID=69445929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911164848.7A Active CN110791451B (zh) | 2019-11-25 | 2019-11-25 | 一株植物乳杆菌jylp-326及其对睡眠的改善应用和产品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110791451B (zh) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112375713A (zh) * | 2020-11-25 | 2021-02-19 | 山东向日葵生物工程有限公司 | 一株长双岐乳杆菌sf-b-27及其应用 |
CN113337428A (zh) * | 2021-06-03 | 2021-09-03 | 海南大学 | 一株植物乳杆菌hnu082及其用途 |
CN114365845A (zh) * | 2022-02-18 | 2022-04-19 | 吉林大学 | 一种植物发酵组合物及其制备方法和应用 |
CN114437997A (zh) * | 2022-04-07 | 2022-05-06 | 山东向日葵生物工程有限公司 | 一种植物乳杆菌sf-l38及其在制备血糖控制产品中的应用 |
CN115747090A (zh) * | 2021-09-06 | 2023-03-07 | 景岳生物科技股份有限公司 | 乳杆菌组合物及其改善抗生素造成的焦虑症的用途 |
CN115873753A (zh) * | 2022-09-16 | 2023-03-31 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 具有缓解特发性震颤和睡眠障碍功能的植物乳杆菌l5及其应用 |
CN115990212A (zh) * | 2022-12-15 | 2023-04-21 | 山东康祐生物科技有限公司 | 一种用于调节gaba-a受体的组合物及其制备方法 |
CN116569999A (zh) * | 2023-05-09 | 2023-08-11 | 沈阳农业大学 | 一种蓝莓汁的发酵方法 |
WO2023161440A1 (en) * | 2022-02-25 | 2023-08-31 | Winclove Holding B.V. | Use of a probiotic composition in a method of treatment of manifestations of self-reported mental exhaustion, preferably with manifestations of low energy levels |
CN117243981A (zh) * | 2023-11-15 | 2023-12-19 | 山东中科嘉亿生物工程有限公司 | 植物乳杆菌jylp-326在制备改善情绪的产品中的应用 |
CN117327631A (zh) * | 2023-11-29 | 2024-01-02 | 山东环亿生物科技有限公司 | 一种改善焦虑抑郁植物乳杆菌株10a-2及其用途 |
CN117683698A (zh) * | 2024-02-04 | 2024-03-12 | 山东中科嘉亿生物工程有限公司 | 一种植物乳杆菌jylp-376及后生元菌剂、制备方法和应用 |
EP4255456A4 (en) * | 2020-12-01 | 2024-09-25 | Servatus Ltd | METHODS TO IMPROVE SLEEP QUALITY |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060057398A (ko) * | 2004-11-23 | 2006-05-26 | 우석대학교 산학협력단 | Gaba 고생산능을 가지는 신규한 락토코커스 유산균,이를 이용한 발효스타터 및 gaba의 생산방법 |
KR20100020121A (ko) * | 2008-08-12 | 2010-02-22 | 두두원발효(주) | 김치유산균으로 발효된 숙면 발효커피 및 그 제조방법 |
CN103045517A (zh) * | 2012-12-30 | 2013-04-17 | 渤海大学 | 一种用于生产γ-氨基丁酸的乳酸菌的培养方法 |
CN103320362A (zh) * | 2013-07-03 | 2013-09-25 | 江南大学 | 一株产谷氨酸脱羧酶的菌株及用其生产γ-氨基丁酸的方法 |
CN108823125A (zh) * | 2018-06-13 | 2018-11-16 | 山东巴元生物科技有限公司 | 一种治疗睡眠障碍益生菌制剂的生产方法及应用 |
CN110106122A (zh) * | 2019-05-30 | 2019-08-09 | 江南大学 | 一种能够改善睡眠的植物乳杆菌及其用途 |
-
2019
- 2019-11-25 CN CN201911164848.7A patent/CN110791451B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060057398A (ko) * | 2004-11-23 | 2006-05-26 | 우석대학교 산학협력단 | Gaba 고생산능을 가지는 신규한 락토코커스 유산균,이를 이용한 발효스타터 및 gaba의 생산방법 |
KR20100020121A (ko) * | 2008-08-12 | 2010-02-22 | 두두원발효(주) | 김치유산균으로 발효된 숙면 발효커피 및 그 제조방법 |
CN103045517A (zh) * | 2012-12-30 | 2013-04-17 | 渤海大学 | 一种用于生产γ-氨基丁酸的乳酸菌的培养方法 |
CN103320362A (zh) * | 2013-07-03 | 2013-09-25 | 江南大学 | 一株产谷氨酸脱羧酶的菌株及用其生产γ-氨基丁酸的方法 |
CN108823125A (zh) * | 2018-06-13 | 2018-11-16 | 山东巴元生物科技有限公司 | 一种治疗睡眠障碍益生菌制剂的生产方法及应用 |
CN110106122A (zh) * | 2019-05-30 | 2019-08-09 | 江南大学 | 一种能够改善睡眠的植物乳杆菌及其用途 |
Non-Patent Citations (1)
Title |
---|
J. DHALIWAL ET AL.: "Lactobacillus plantarum MTCC 9510 supplementation protects from chronic unpredictable and sleep deprivation-induced behaviour, biochemical and selected gut microbial aberrations in mice", 《JOURNAL OF APPLIED MICROBIOLOGY 》 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112375713B (zh) * | 2020-11-25 | 2022-07-05 | 山东向日葵生物工程有限公司 | 一株长双岐乳杆菌sf-b-27及其应用 |
CN112375713A (zh) * | 2020-11-25 | 2021-02-19 | 山东向日葵生物工程有限公司 | 一株长双岐乳杆菌sf-b-27及其应用 |
EP4255456A4 (en) * | 2020-12-01 | 2024-09-25 | Servatus Ltd | METHODS TO IMPROVE SLEEP QUALITY |
CN113337428A (zh) * | 2021-06-03 | 2021-09-03 | 海南大学 | 一株植物乳杆菌hnu082及其用途 |
CN113337428B (zh) * | 2021-06-03 | 2023-06-06 | 海南大学 | 一株植物乳杆菌hnu082及其用途 |
CN115747090A (zh) * | 2021-09-06 | 2023-03-07 | 景岳生物科技股份有限公司 | 乳杆菌组合物及其改善抗生素造成的焦虑症的用途 |
CN114365845A (zh) * | 2022-02-18 | 2022-04-19 | 吉林大学 | 一种植物发酵组合物及其制备方法和应用 |
WO2023161440A1 (en) * | 2022-02-25 | 2023-08-31 | Winclove Holding B.V. | Use of a probiotic composition in a method of treatment of manifestations of self-reported mental exhaustion, preferably with manifestations of low energy levels |
CN114437997A (zh) * | 2022-04-07 | 2022-05-06 | 山东向日葵生物工程有限公司 | 一种植物乳杆菌sf-l38及其在制备血糖控制产品中的应用 |
CN114437997B (zh) * | 2022-04-07 | 2022-06-10 | 山东向日葵生物工程有限公司 | 一种植物乳杆菌sf-l38及其在制备血糖控制产品中的应用 |
CN115873753B (zh) * | 2022-09-16 | 2023-10-20 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 具有缓解特发性震颤和睡眠障碍功能的植物乳杆菌l5及其应用 |
CN115873753A (zh) * | 2022-09-16 | 2023-03-31 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 具有缓解特发性震颤和睡眠障碍功能的植物乳杆菌l5及其应用 |
CN115990212A (zh) * | 2022-12-15 | 2023-04-21 | 山东康祐生物科技有限公司 | 一种用于调节gaba-a受体的组合物及其制备方法 |
CN116569999A (zh) * | 2023-05-09 | 2023-08-11 | 沈阳农业大学 | 一种蓝莓汁的发酵方法 |
CN117243981A (zh) * | 2023-11-15 | 2023-12-19 | 山东中科嘉亿生物工程有限公司 | 植物乳杆菌jylp-326在制备改善情绪的产品中的应用 |
CN117327631A (zh) * | 2023-11-29 | 2024-01-02 | 山东环亿生物科技有限公司 | 一种改善焦虑抑郁植物乳杆菌株10a-2及其用途 |
CN117327631B (zh) * | 2023-11-29 | 2024-01-26 | 山东环亿生物科技有限公司 | 一种改善焦虑抑郁植物乳杆菌株10a-2及其用途 |
CN117683698A (zh) * | 2024-02-04 | 2024-03-12 | 山东中科嘉亿生物工程有限公司 | 一种植物乳杆菌jylp-376及后生元菌剂、制备方法和应用 |
CN117683698B (zh) * | 2024-02-04 | 2024-05-14 | 山东中科嘉亿生物工程有限公司 | 一种植物乳杆菌jylp-376及后生元菌剂、制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN110791451B (zh) | 2020-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110791451B (zh) | 一株植物乳杆菌jylp-326及其对睡眠的改善应用和产品 | |
CN107760620B (zh) | 一株改善易胖体质及子代体重的植物乳杆菌及应用 | |
CN112375713B (zh) | 一株长双岐乳杆菌sf-b-27及其应用 | |
CN114574406B (zh) | 鼠李糖乳杆菌菌株wka55及其在制备防治酒精性肝损伤制品方面的用途与产品 | |
CN116814510B (zh) | 一株能够预防或改善阿尔茨海默症的鼠李糖乳杆菌opb41和应用 | |
CN112592871B (zh) | 一种干酪乳杆菌jylc-374及其在改善男性前列腺产品中的应用 | |
CN115895966B (zh) | 一株辅助缓解痛风的两歧双歧杆菌bl002及其应用 | |
CN108295096B (zh) | 菌株在预防和治疗霉菌性、细菌性阴道炎制剂中的应用 | |
CN116179441A (zh) | 一株预防、改善以及治疗宠物猫食欲不振症状的乳酸片球菌jypa-16及其应用 | |
CN116445356A (zh) | 一种调节肠道菌群及增强免疫力的动物双歧杆菌乳亚种ba67及其应用 | |
CN112625983A (zh) | 一种对腹泻有治疗效果的干酪乳杆菌L.Casei21及其应用 | |
CN115322932A (zh) | 一株具有解酒醒酒能力的植物乳植杆菌和应用 | |
CN112592872B (zh) | 一种能够消除体内自由基的长双歧杆菌jblc-141及其应用 | |
CN116211956B (zh) | 一种调节肠道和/或改善肥胖的组合物和制备方法、一种咀嚼片及其应用 | |
CN111616368A (zh) | 一种缓解便秘功能的组合物及其制备方法 | |
CN115261251B (zh) | 嗜热链球菌s869及其在调节免疫和调节肠道功能中的应用 | |
CN115322940B (zh) | 一种植物乳杆菌及其助眠抗抑郁产品和应用 | |
CN118146982A (zh) | 一种可降解尿酸的芽孢杆菌、生物制剂及其制备方法 | |
CN114657110B (zh) | 一种发酵乳杆菌iob802及其改善睡眠障碍的用途 | |
CN117987290A (zh) | 一种具有改善免疫力、助眠特性的鼠李糖乳杆菌 | |
CN112458004B (zh) | 一种动物双歧杆菌乳亚种bp026及其应用 | |
CN116286537B (zh) | 具有辅助减肥作用的副干酪乳杆菌gf045及其应用 | |
CN114668151B (zh) | 一种乳双歧杆菌sf-b21在制备降尿酸产品中的应用 | |
CN118421501B (zh) | 一株具有降血糖功能的哈尔滨施莱弗乳杆菌jndm及其应用 | |
CN115806911B (zh) | 一株植物乳杆菌、分离方法、用途和药品、食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20241024 Address after: 262500 Intersection of Qiwang Road and Jizhou Road, Jiaoshan Economic Development Zone, Shaozhuang Town, Qingzhou City, Weifang City, Shandong Province Patentee after: Minsheng Zhongke Jiayi (Shandong) Biotechnology Co.,Ltd. Country or region after: China Address before: 9777 Qiwang Road, Qingzhou City, Weifang City, Shandong Province 262500 Patentee before: SHANDONG ZHONGKE-JIAYI BIO-ENGINEERING CO.,LTD. Country or region before: China |